文献速递白血病

为慢性髓性白血病基于基因组学的风险评估奠定基础

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
PubMed 文献 · Leukemia · 2019-06-17

本文综述了慢性髓性白血病(CML)患者在初诊、治疗失败和疾病转化阶段中癌症相关基因突变的研究报道,讨论了突变频率与类型,并概述了当前突变评估的局限性和未来报告建议。超过十年的突变研究汇总表明,一组有限的癌症相关基因在CML中确实反复突变,部分频率较高。基因组学研究有潜力为根据临床和基因组风险改进诊断风险分类奠定基础,并实现TKI耐药的更精准早期识别。

要点

  • 诊断时BCR-ABL1转录本水平无既定预后影响,不能指导一线TKI选择。
  • 约50%的TKI耐药患者可检测到BCR-ABL1突变,但罕见导致原发耐药。
  • 超过十年的突变研究提示一组有限的癌症相关基因在CML中反复突变,部分频率较高。

核心结论

  • 超过十年的突变研究汇总表明,一组有限的癌症相关基因在CML中确实反复突变,部分频率较高。
  • 基因组学研究有潜力为根据临床和基因组风险改进诊断风险分类奠定基础,并实现TKI耐药的更精准早期识别。

研究设计与样本

  • 综述:回顾报道CML患者在不同疾病阶段中癌症相关基因突变的出版物。
  • 讨论初诊时和治疗失败及转化时此类变异的频率和类型。

主要发现

  • 诊断时BCR-ABL1转录本水平无既定预后影响,不能指导一线TKI选择。
  • BCR-ABL1突变在约50%的TKI耐药患者中检测到,但罕见导致原发耐药。
  • 其他耐药机制大部分未表征,且无其他常规分子检测策略促进TKI耐药的评估和进一步分层。

关键数值与推荐

  • BCR-ABL1突变在约50%的TKI耐药患者中检测到。
  • 超过十年的突变研究汇总表明,一组有限的癌症相关基因在CML中反复突变,部分频率较高。

临床怎么用

  • 基因组分析在诊断、耐药和疾病转化时可能增强患者管理决策,类似其他癌症。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patient management regarding how to more reliably predict treatment failure at the time of diagnosis and how to select frontline tyrosine kinase inhibitor (TKI) therapy for optimal outcome. The BCR-ABL1 transcript level at diagnosis has no established prognostic impact and cannot guide frontline TKI selection. BCR-ABL1 mutations are detected in ~50% of TKI resistant patients but are rarely responsible for primary resistance. Other resistance mechanisms are largely uncharacterized and there are no other routine molecular testing strategies to facilitate the evaluation and further stratification of TKI resistance. Advances in next-generation sequencing technology has aided the management of a growing number of other malignancies, enabling the incorporation of somatic mutation profiles in diagnosis, classification, and prognostication. A largely unexplored area in CML research is whether expanded genomic analysis at diagnosis, resistance, and disease transformation can enhance patient management decisions, as has occurred for other cancers. The aim of this article is to review publications that reported mutated cancer-associated genes in CML patients at various disease phases. We discuss the frequency and type of such variants at initial diagnosis and at the time of treatment failure and transformation. Current limitations in the evaluation of mutants and recommendations for future reporting are outlined. The collective evaluation of mutational studies over more than a decade suggests a limited set of cancer-associated genes are indeed recurrently mutated in CML and some at a relatively high frequency. Genomic studies have the potential to lay the foundation for improved diagnostic risk classification according to clinical and genomic risk, and to enable more precise early identification of TKI resistance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Branford S, Kim DDH, Apperley JF, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019. PMID: 31209280. doi:10.1038/s41375-019-0512-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。